Nav: Home

Copay assistance is the problem, not the solution to high drug prices

October 10, 2016

1. Copay assistance is the problem, not the solution to high drug prices, policy experts say
All URLs go live when the embargo lifts

Copay assistance is part of the drug pricing problem, not a solution to it, according to several health policy experts in a commentary published in Annals of Internal Medicine. The experts offer five reasons why programs like the one offered by Mylan, the pharmaceutical company responsible for the controversial Epi-Pen price hike, look like a boon for public health but are actually a recipe for higher healthcare costs.

As drug companies raise medication prices, insurance companies reduce coverage, and consumers are left paying higher out-of-pocket costs. Pharmaceutical companies could ease consumer burden by lowering prices, but they often opt for Mylan's strategy instead. That is, they offer coupons to offset patient costs or form charities to administer support programs for patients with government insurance. The authors outline several reasons why these copay assistance programs will lead to more expensive drugs in the future and also offer suggestions for health care policy makers to mitigate their inflationary impact.

A second drug pricing commentary published in Annals suggests that current pricing policy recommendations ignore public health implications. The authors argue that reducing payment to pharmaceutical companies could affect the types of drugs that are brought to the marketplace. For example, under the current reimbursement system, pharmaceutical companies often earn higher profits from drugs that patients take every day for maintenance of common conditions. However, if drug prices were commensurate with cost-effectiveness, prices would be higher for cures and prevention and companies would invest more in the types of drugs that stand to yield a greater social value. The authors suggest ways in which policy makers could redirect their energy toward innovation-innovation tradeoffs instead of the current innovation-access model.

Note: For embargoed PDFs, please contact Cara Graeff. To interview the lead author of the first commentary, Dr. Peter Ubel, please contact Ellen de Graffenreid at or 919-660-1922. To speak with the author of the second commentary, Ms. Rachel Sachs, please contact Neil Schoenherr at
Also new in this issue:

Savings from ACOs - Building on Early Successes

J. Michael McWilliams, MD, PhD
Ideas and Opinions

Calibration of the Pooled Cohort Equations for Atherosclerotic Cardiovascular Disease: An Update
Nancy R. Cook, ScD; Paul M. Ridker, MD
Research and Reporting Methods

Patient Experience Must Move Beyond Bad Apples
Azita Hamedani, MD, MPH, MBA; Basmah Safdar, MD; Emily Aaronson, MD; Thomas H. Lee, MD
Ideas and Opinions

American College of Physicians

Related Public Health Articles:

Public health guidelines aim to lower health risks of cannabis use
Canada's Lower-Risk Cannabis Use Guidelines, released today with the endorsement of key medical and public health organizations, provide 10 science-based recommendations to enable cannabis users to reduce their health risks.
Study clusters health behavior groups to broaden public health interventions
A new study led by a University of Kansas researcher has used national health statistics and identified how to cluster seven health behavior groups based on smoking status, alcohol use, physical activity, physician visits and flu vaccination are associated with mortality.
Public health experts celebrate 30 years of CDC's prevention research solutions for communities with health disparities
It has been 30 years since CDC created the Prevention Research Centers (PRC) Program, currently a network of 26 academic institutions across the US dedicated to moving new discoveries into the communities that need them.
Public health experts support federally mandated smoke-free public housing
In response to a new federal rule mandating smoke-free policies in federally funded public housing authorities, three public health experts applaud the efforts of the US Department of Housing and Urban Development to protect nonsmoking residents from the harmful effects of tobacco exposure.
The Lancet Public Health: UK soft drinks industry levy estimated to have significant health benefits, especially among children
The UK soft drinks industry levy, due to be introduced in April 2018, is estimated to have significant health benefits, especially among children, according to the first study to estimate its health impact, published in The Lancet Public Health.
More Public Health News and Public Health Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#534 Bacteria are Coming for Your OJ
What makes breakfast, breakfast? Well, according to every movie and TV show we've ever seen, a big glass of orange juice is basically required. But our morning grapefruit might be in danger. Why? Citrus greening, a bacteria carried by a bug, has infected 90% of the citrus groves in Florida. It's coming for your OJ. We'll talk with University of Maryland plant virologist Anne Simon about ways to stop the citrus killer, and with science writer and journalist Maryn McKenna about why throwing antibiotics at the problem is probably not the solution. Related links: A Review of the Citrus Greening...